Neuromod develops non-invasive neuromodulation devices designed to treat tinnitus through bimodal stimulation. The company’s flagship system, Lenire, combines auditory stimulation with targeted electrical stimulation of the tongue. Its approach focuses on modulating neural pathways involved in tinnitus perception without surgical intervention. Neuromod positions its technology within regulated clinical treatment contexts.

The technology delivers precisely timed sound through headphones alongside gentle electrical stimulation to the tongue via a mouthpiece. This bimodal stimulation is designed to engage and retrain auditory and somatosensory neural circuits implicated in tinnitus. By pairing these two modalities, the system aims to promote adaptive neural plasticity that reduces tinnitus symptoms over time. Treatment protocols are structured and intended for repeated use under clinical guidance.

Neuromod targets individuals with chronic tinnitus seeking non-pharmacological treatment options. The Lenire system is prescribed and used within established healthcare pathways rather than consumer wellness settings. Its focus reflects growing interest in multisensory neuromodulation approaches to addressing conditions driven by maladaptive neural activity.